Matches in SemOpenAlex for { <https://semopenalex.org/work/W52749595> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W52749595 endingPage "8" @default.
- W52749595 startingPage "911" @default.
- W52749595 abstract "Tinea pedis is the most common chronic fungal infection. Naftifine hydrochloride is a topical antifungal of the allylamine class, displaying fungicidal activity and clinically significant anti-bacterial and anti-inflammatory effects.To evaluate the efficacy and safety of two-weeks once daily application of naftifine gel 2% in the treatment of tinea pedis.At baseline, 1715 subjects were randomly assigned 2:1 to naftifine gel 2% (n=1144) and vehicle (n=571). Efficacy consisting of mycologic determination (KOH and dermatophyte cultures) and scoring of clinical symptom severity was evaluated at baseline and weeks 2, 4, and 6. Efficacy was analyzed in 1174 subjects (n=782, naftifine; n=392, vehicle) with a positive baseline dermatophyte culture and KOH for whom week 6 assessments were available. Safety was evaluated by adverse events (AE) and laboratory values in 1714 subjects (n=1143, naftifine; n=571, vehicle).Subjects treated with naftifine gel 2% for interdigital-type tinea pedis demonstrated greater improvement from baseline for complete cure (P=0.001), mycological cure (P<0.0001), and treatment effectiveness (P<0.0001) as early as 2 weeks when compared to vehicle; however the highest response rates were seen 4-weeks post treatment (P<0.0001, for all endpoints). Statistically significant results for complete cure, mycological cure, and treatment effectiveness (P<0.0001, for all endpoints) were also seen at week 6 among subjects with moccasin-type tinea pedis. Treatment related adverse events were minimal.Treatment with naftifine gel 2% applied once daily for two weeks is well-tolerated and is effective in treating both interdigital-type and moccasin-type tinea pedis. Continuous improvement is observed from the end of treatment to four-weeks after treatment cessation among key outcome measures (complete cure, mycological cure, and treatment effectiveness) as well as clinical signs and symptoms (erythema, scaling, and pruritus)" @default.
- W52749595 created "2016-06-24" @default.
- W52749595 creator A5007250593 @default.
- W52749595 creator A5008079209 @default.
- W52749595 creator A5014429343 @default.
- W52749595 creator A5024813284 @default.
- W52749595 creator A5027081268 @default.
- W52749595 creator A5056578257 @default.
- W52749595 creator A5058719845 @default.
- W52749595 creator A5058903008 @default.
- W52749595 creator A5083669395 @default.
- W52749595 date "2013-08-01" @default.
- W52749595 modified "2023-09-23" @default.
- W52749595 title "Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials." @default.
- W52749595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23986165" @default.
- W52749595 hasPublicationYear "2013" @default.
- W52749595 type Work @default.
- W52749595 sameAs 52749595 @default.
- W52749595 citedByCount "3" @default.
- W52749595 countsByYear W527495952015 @default.
- W52749595 countsByYear W527495952018 @default.
- W52749595 countsByYear W527495952022 @default.
- W52749595 crossrefType "journal-article" @default.
- W52749595 hasAuthorship W52749595A5007250593 @default.
- W52749595 hasAuthorship W52749595A5008079209 @default.
- W52749595 hasAuthorship W52749595A5014429343 @default.
- W52749595 hasAuthorship W52749595A5024813284 @default.
- W52749595 hasAuthorship W52749595A5027081268 @default.
- W52749595 hasAuthorship W52749595A5056578257 @default.
- W52749595 hasAuthorship W52749595A5058719845 @default.
- W52749595 hasAuthorship W52749595A5058903008 @default.
- W52749595 hasAuthorship W52749595A5083669395 @default.
- W52749595 hasConcept C126322002 @default.
- W52749595 hasConcept C16005928 @default.
- W52749595 hasConcept C168563851 @default.
- W52749595 hasConcept C197934379 @default.
- W52749595 hasConcept C203092338 @default.
- W52749595 hasConcept C2777220567 @default.
- W52749595 hasConcept C2992053201 @default.
- W52749595 hasConcept C535046627 @default.
- W52749595 hasConcept C71924100 @default.
- W52749595 hasConceptScore W52749595C126322002 @default.
- W52749595 hasConceptScore W52749595C16005928 @default.
- W52749595 hasConceptScore W52749595C168563851 @default.
- W52749595 hasConceptScore W52749595C197934379 @default.
- W52749595 hasConceptScore W52749595C203092338 @default.
- W52749595 hasConceptScore W52749595C2777220567 @default.
- W52749595 hasConceptScore W52749595C2992053201 @default.
- W52749595 hasConceptScore W52749595C535046627 @default.
- W52749595 hasConceptScore W52749595C71924100 @default.
- W52749595 hasIssue "8" @default.
- W52749595 hasLocation W527495951 @default.
- W52749595 hasOpenAccess W52749595 @default.
- W52749595 hasPrimaryLocation W527495951 @default.
- W52749595 hasRelatedWork W2065994215 @default.
- W52749595 hasRelatedWork W2352875693 @default.
- W52749595 hasRelatedWork W2369655193 @default.
- W52749595 hasRelatedWork W2386499618 @default.
- W52749595 hasRelatedWork W2389819105 @default.
- W52749595 hasRelatedWork W2394749827 @default.
- W52749595 hasRelatedWork W2905966959 @default.
- W52749595 hasRelatedWork W3178609731 @default.
- W52749595 hasRelatedWork W4225006142 @default.
- W52749595 hasRelatedWork W4233197666 @default.
- W52749595 hasVolume "12" @default.
- W52749595 isParatext "false" @default.
- W52749595 isRetracted "false" @default.
- W52749595 magId "52749595" @default.
- W52749595 workType "article" @default.